山东大学耳鼻喉眼学报 ›› 2018, Vol. 32 ›› Issue (5): 110-113.doi: 10.6040/j.issn.1673-3770.0.2018.034

• ·综述· • 上一篇    下一篇

甲状腺相关性眼病的诊断及治疗进展

朱明娟1,邢凯2,亢泽峰3,刘健3   

  1. 1.青海省中医院眼科, 青海 西宁 810000;
    2.北京市昌平区中医医院眼科, 北京 102200;
    3.中国中医科学院眼科医院, 北京 100040
  • 收稿日期:2018-01-15 出版日期:2018-09-20 发布日期:2018-09-20
  • 通讯作者: 邢凯. E-mail:cxingbkail@163.com

Diagnosis and treatment of thyroid-associated ophthalmopathy

ZHU Mingjuan1, XING Kai2, KANG Zefeng3, LIU Jian3   

  1. Changping District Hospital of Traditional Chinese Medicine, Beijing 102200, China;3. Eye Hospital of Chinese Academy of Traditional Chinese Medicine, Beijing 100040, China
  • Received:2018-01-15 Online:2018-09-20 Published:2018-09-20

HTML

PDF (PC)

642

摘要： 甲状腺相关性眼病是一种与甲状腺功能异常相关的器官特异性自身免疫性疾病,该病最常见的是腺外器官受累,从而影响患者外观;重者可以导致复视、视力下降甚至失明,然其发病机制尚不完全清楚,目前临床上的治疗并不能达到100%满意。且临床上治疗方法有多种。实验室检查其主要的病理改变是眼睛的软组织和眼外肌的一些免疫炎性反应,但是确切的发病病理生化等机制尚不清楚。临床上诊疗难度大,就本病在临床诊断及治疗的最新研究进展进行综述。

关键词: 甲状腺相关性眼病, 研究进展, 临床诊断

Abstract: Thyroid-related ophthalmopathy is an organ-specific autoimmune disease associated with abnormal thyroid function. The extra-glandular ocular involvement affects the appearance of the patient; severe cases can present with diplopia, decreased vision, or even blindness. The pathogenesis is not yet fully understood, and the current clinical therapeutic approaches cannot cure or provide relief to all patients. Moreover, there are many clinical treatment methods. Histopathological examination of the ocular soft tissue and extra-ocular muscles shows some immune inflammatory response, but the exact pathogenesis of this disease is not clear. This article reviews the latest research on the clinical diagnosis and treatment of thyroid-related ophthalmopathy.

Key words: Research progress, Thyroid-associated ophthalmopathy, Clinical diagnosis

中图分类号: 

  • R777.1
[1] Henfelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease[J]. Rev Endocr Metab Disond, 2000, 1(1-2):87-95.
[2] 周慧芳, 范先群. 甲状腺相关性眼病的治疗进展[J]. 中国实用眼科杂志,2008,26(8):760-763.
[3] 明健, 魏锐利. 17-β雌二醇在TAO成纤维细胞氧化应激中的保护作用研究[D]. 上海:第二军医大学,2013.
[4] Stein JD, Childers D, Gupta S. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease[J]. Arch Ophthalmol, 2015, 3(133):290-293.
[5] 赵立全, 魏锐利. 细胞因子与眼眶成纤维细胞[J]. 中国实用眼科杂志,2010,28(7):685-688.
[6] Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves disease,and thyroid-associated ophthalmopathy[J]. Thyroid, 2008, 18(9):953-958.
[7] Pan D, Shin YH, Gopalakrishnan G, et al. Regulatory T cells in Graves’disease[J]. Clin Endocrinol, 2009, 71(4):587-593.
[8] 徐霁, 李华, 蔡春华, 等. 血清IL-17,IL-21与Graves眼病相关性研究[J]. 中国煤炭工业医学杂志,2017,4(20):424-426. XU Ji, LI Hua, CAI Chunhua, et al. Correlations between il-17, il-21 levels and graves ophthalmopathy[J]. Chin J Coal Indust Med, 2017, 4(20):424-426.
[9] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy Versus sham irradiation in patients with mind Graveshtllalmathy[J]. J Clin Endorcrinol Metab, 2004, 89(1):15-20.
[10] Bahn RS. Thyrotropin receptor expression in orbital adipose connective tissues fron patients with thyroid-associated ophthalmopathy[J]. Thyroid, 2002, 12(3):193-195.
[11] Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves disease is mediated through the insulin-like growth factor I receptor pathway[J]. J Immunol, 2003, 170(12):6348-6354.
[12] Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community-a twenty-year follow-up of the Whickham survey[J]. Clin Endocrinol, 1995, 43(1):55-69.
[13] Khalilzadeh O, Noshad S, et al. Graves ophthalmopathy: a review of immunogenetics[J]. Curr Genomics, 2011, 12(8):564-575.
[14] Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort[J]. Ophthalmology, 1996, 103(6):958-962.
[15] 栾洁. 甲状腺相关眼病的诊治[J]. 铁道医学,2001,29(4):213-214.
[16] Phan TT, Sun L, Bay BH, et al. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring[J]. J Trauma, 2003, 54(6):1212-1224.
[17] 钱昱,李玉珍,梁文君,等. 甲状腺相关性眼病的研究及治疗进展[J]. 现代生物医学进展,2017,6(17):3195-3200. QIAN Yu, LI Yuzhen, LIANG Wenjun, et al. Progress and review in thyroid-associated ophthalmopathy[J]. Prog Modern Biom, 2017, 6(17):3195-3200.
[18] Scruggs RT, Black EH. Thyroid eye disease wirh significant levator involvement and ptosis:a case report[J]. Ophthal Plast Reconstr surg, 2015, 31(6):153-154.
[19] Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease[J]. Autoimmun Rev, 2014, 13(4-5):398-402.
[20] Van Dyk HJ. Orbital Graves disease:a modification of the “NO SPECS” classification[J]. Ophthalmology, 1981, 88(6):479-483.
[21] Bartalena L. Diagnosis management of Grave disease: a global overview[J]. Nat Rev Endocrinol, 2013, 9(12):723-734.
[22] 罗兴中,罗红强,杨海军. 甲状腺相关性眼病的研究现状[J]. 中国实用眼科杂志,2012,3(30):236-239.
[23] Phelps PO, Williams K. Thyroid eye disease for the primary care physician[J]. Dis Mon, 2014, 60(6):292-298.
[24] 郭剑津,刘超.Graves眼病的治疗:系统综述及meta分析[J]. 中华内分泌代谢杂志,2010,1(26):69-72.
[25] Henfelder AE. Pathsgenesis of ophthalmopathy in autoimmune thyroid disease[J]. Rev Endocr Metab Disond, 2000, 1(1-2):87-95.
[26] Naik VM, Naik MN, Goldberg RA, et al. DouglasRS. Immunopathogenesis of thyroid eye disease:emerging paradigms[J]. Surv Ophthalmol, 2010, 55(3):215-226.
[27] Stein JD, Kim DS, Niziol LM, et al. Differences in rates of glaucoma among Asian Americans and other racial groups[J]. Ophthalmology, 2011, 118(6):1031-1037.
[28] 左新河,牧亚峰. 从络病理论探析甲状腺相关性眼病的辨治[J]. 湖北中医杂志,2017,39(10):31-33.
[29] 王慧琴,邵迎新,刘文. 中西医结合治疗甲状腺相关性眼病[J]. 中华现代中西医杂志,2005,14(11):996.
[30] 顾明君,刘志民,朱莉,等. 奥曲肽和泼尼松治疗甲状腺相关性眼病的随机对照研究[J]. 第二军医大学学报,2002,23(5):540-543. GU Mingjun, LIU Zhimin, ZHU Li, et al. Randomized control trial of subcutaneous octreotide and oral prednisone in treatment of thyroid eye disease[J]. Acad J Sec Mil Med Univ, 2002, 23(5):540-543.
[31] 肖屏风. 中西医结合治疗甲状腺相关眼病疗效观察[J]. 临床医学进程,2009,18(7):530,544.
[32] Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves orbitopathy(EUGOGO)on management of Graves orbitopathy[J]. Thyroid, 2008, 18(3):333-346.
[33] 许薇薇,程金伟,蔡季平,等. Graves眼病治疗途径的现况及展望[J]. 中国实用眼科杂志,2007,25(8):823-825.
[34] 朱本章,朱江,乔文颖. Graves’眼病的诊断和治疗进展[J]. 内科急危重症杂志,2002,8(1):40-43.
[35] 李东豪,邱红红,张金山,等. 生长抑素治疗甲状腺相关性眼病的疗效分析[J]. 中国实用眼科杂志,2009,27(12):1372-1373. LI Donghao, QIU Honghong, ZHANG Jinshan, et al. Treatment for thyriod associated ophthalmopathy with Octreotide[J]. Chin J Pract Ophthalmol, 2009, 27(12):1372-1373.
[36] 王宇鹰,王养忠. 局部注射治疗甲状腺相关眼病32例报告[J]. 实用诊断与治疗杂志,2007,21(9):709-710.
[37] Newman-Casey PA, Talwar N, Nan B, et al. The relationship between components of metabolic syndrome and open-angle glaucoma[J]. Ophthalmology, 2011, 118(7):1318-1326.
[38] 田蓉,匡安仁,秦卫仕,等. 99Tc-MDP与免疫抑制疗法治疗Grave’眼病的对比研究[J]. 中华核医学杂志,2000,20(6):250-253.
[39] Ponto KA, Kanitz M, Olivo PD, et al. Clinical relevance of thyroid-stimulating immunoglobulins in graves’ophthalmopathy[J]. Ophthalmology,2011,118(11):2279-2285.
[40] Lytton SD, Ponto KA, Kanitz M, et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2010, 95(5):2123-2131.
[41] 王毅,赵海萍,苏帆,等. 切除眼眶深外侧和内侧骨壁的减压术治疗甲状腺相关眼病二例[J]. 中华眼科杂志,2010,46(9):846-848.
[42] Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy[J]. Med Clin North Am, 2012, 96(2):311-328.
[43] Bartalena L, Baldeschi L, et al. The 2016 European Thyriod Association/European group on Graves Orbitopathy Guidelines for the Management of Graves orbitopathy[J]. Eur Thyroid J, 2016, 5(1):9-26.
[44] Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves orbitopathy[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26(3):325-337.
[45] Tallstedt L, Lundell G, Blomgren H, et al. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment?[J]. Eur J Endocrinol, 1994, 130(5):494-497.
[46] Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole[J]. J Clin Endocrinol Metab, 1994, 79(2):542-546.
[47] Huang CC, Chan WL, Chen YC, et al. Statin use in patients with asthma: a nationwide population-based study[J]. Eur J ClinInvest, 2011, 41(5):507-512.
[48] Semb AG, HolmeI, Kvien TK, et al. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering(IDEAL)trial[J]. Rheumatology, 2011, 50(2): 324-329.
[49] McCarey DW, McInnesI B, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis(TARA): double-blind, randomised placebo-controlled trial[J]. Lancet, 2004, 363(9426):2015-2021.
[50] Hu Y, Tong G, Xu W, et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis[J]. Diab Vasc Dis Res, 2009, 6(4):262-268.
[51] Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves orbitopathy[J]. N EngI J Med, 2011, 364(20):1920-1931.
[52] Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms[J]. Nat Rev Drug Discov, 2005, 4(12):977-987.
[1] 魏超, 张晗. 多焦点人工晶状体的临床应用进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 29-35.
[2] 章如新. 变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 3-6.
[3] 赵静静1，杨学秋1，庄文娟2 . 定量检测LASIK手术对视网膜影响的研究进展[J]. 山东大学耳鼻喉眼学报, 2012, 26(3): 79-82.
[4] 刘雯. 近距离工作诱发暂时性近视对近视发展的影响[J]. 山东大学耳鼻喉眼学报, 2012, 26(3): 83-85.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发